medizin
We are thrilled to announce the successful completion of the EU Horizon 2020 project ASPIRE!
Our collaborative efforts have led to the development of an innovative new prototype for one-click perfusion analysis of ASL images. You can find a demo version of ExploreASL in mTRIAL here
ASL (Arterial Spin Labeling) is a cutting-edge MR imaging technique for contrast agent free perfusion imaging of the brain. It holds immense promise in improving the diagnosis and treatment monitoring of Alzheimer’s Disease. Especially for older adults with cardiovascular risk factors, ASL could be a game-changer.
Thank you all for your hard work and dedication, Gold Standard Phantoms,
Hochschule Darmstadt, Amsterdam UMC and mediri GmbH
Tired of deploying image evaluation scripts on your local machine? ASL image evaluation for brain perfusion analysis can be as easy as this: click, click.
Watch this video to see how images are uploaded from your local network to the central mTRIAL server – pseudonymization on the fly and image categorizaton included.
Just imagine… evaluating brain perfusion on arterial spin labeling images was just one click away. Watch this video to see how we implemented Explore ASL in our mTRIAL platform to facilitate and standardize your next clinical study on neurodegenerative diseases.
Stay tuned to see how easy your data reaches mTRIAL.
Contact us for more information on ASL imaging and analysis.
World Multiple Sclerosis Day, as a day of global solidarity, emphasizes the need to raise awareness of this disease, improve diagnosis and treatment, and fund research to curb multiple sclerosis.
At mediri we develop and refine structural analysis methods to support the diagnosis and follow-up of multiple sclerosis.
An important imaging biomarker for MS is smouldering lesions. Their AI-aided detection on MR images also makes disease activity visible that cannot be seen with the naked eye.
Today is International Clinical Trials Day. Let’s celebrate this event and raise awareness about clinical trials while expressing our gratitude to all clinical research professionals worldwide.
Last week, the first workshop in the BosomShield project was hosted by the IBIB PAN (Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences) in Warsaw.
Our Ph.D. candidate, Yaqeen Ali, presented his achievements towards federated learning approaches for breast cancer classification. The entire workshop discussion focused on how AI is shaping medical imaging, particularly in breast cancer. We would like to express our gratitude to IBIB PAN (https://ibib.pl/en/) for organizing this inspiring session.
More information on the Marie Sklodowska-Curie Doctorate network Bosomshield: https://bosomshield.eu/
Did you know that Parkinson’s disease is the fastest-growing brain disease? At the same time, Parkinson’s disease is so variable, almost no 2 individuals’ symptoms and progression are the same. That is why at mediri, we are working every day to improve the diagnosis and therapy of Parkinson’s disease using advanced MR Imaging and Focused Ultrasound techniques.
For more details, you can have a look at this publication on automatic planning of MR-guided transcranial focused ultrasound treatment or this review article on blood-brain barrier dysfunction imaging.
We proudly announce that mediri has once again received the Digital Innovator 2024 award from CHIP in the category ”medical technology“.
In times of digitization, CHIP and data analysis specialist Globis Consulting have studied the innovative power of German companies and institutes in digitization. CHIP is known as one of the top recommended brands. See the full ranking here.
Today is International Day of Radiology to promote the seismic impact of radiology on medicine – earlier detection, fewer surgeries, and game-changing treatment outcomes. Analyzing radiological images in multi centric clinical studies can be challenging considering standardization and patient data privacy.
Mediri is constantly evolving its image data management platform mTRIAL for secure and reliable central reads in clinical studies. Currently, mTRIAL is getting ready for RANO 2.0 evaluation of low- and high-grade gliomas according to the recently published update by Wen et al. Stay posted.
New office. New Neighbours. New view.
It’s done! We have offically moved to Am Taubenfeld 21/1 in 69123 Heidelberg.
